Dresser L D, Rybak M J
Department of Pharmacy Practice, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, Michigan, USA.
Pharmacotherapy. 1998 May-Jun;18(3):456-62.
The oxazolidinones are a new synthetic class of antimicrobials structurally unrelated to any agent presently marketed. Data pertaining to these compounds, with respect to their pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, and bacteriologic activity, focusing on the analogs linezolid (PNU 100766) and eperezolid (PNU 100592), were retrieved by MEDLINE search and review of relevant abstracts presented at recent clinical conferences. Since the drugs are still investigational, we obtained in vitro and animal data as well as available human studies. The oxazolidinones have bacteriostatic activity against a number of important pathogens including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and vancomycin-resistant enterococci. They appear to be efficacious and well tolerated both orally and parenterally. Their role remains to be elucidated by clinical trials.
恶唑烷酮类是一类新的合成抗菌药物,其结构与目前市场上销售的任何药物均无关联。通过医学文献数据库(MEDLINE)检索以及查阅近期临床会议上发表的相关摘要,获取了有关这些化合物的药理学、药代动力学、药效学、作用机制和细菌学活性的数据,重点关注利奈唑胺(PNU 100766)和依哌唑胺(PNU 100592)等类似物。由于这些药物仍处于研究阶段,我们获取了体外和动物实验数据以及现有的人体研究资料。恶唑烷酮类对多种重要病原体具有抑菌活性,包括耐甲氧西林金黄色葡萄球菌、耐青霉素肺炎链球菌和耐万古霉素肠球菌。它们口服和注射给药似乎均有效且耐受性良好。其作用仍有待临床试验阐明。